Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes

touchREV Endocrinol. 2022 Jun;18(1):27-34. doi: 10.17925/EE.2022.18.1.27. Epub 2022 May 20.

Abstract

Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care.

Keywords: Automated insulin delivery; continuous glucose monitoring; dual hormone pump; glycemic management; hybrid closed loop system; time in range; type 1 diabetes mellitus.

Publication types

  • Review

Grants and funding

Support: No funding was received in the publication of this article.